** Shares of genetics testing firm Tempus AI TEM.O up 16.8% to $50.40, nearly one-mth high, on Weds after announcing multi-year collaborations with British drugmaker AstraZeneca AZN.L and Pathos AI
** Chicago, Illinois-based co early Weds said will work together to build multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, develop therapeutics for broader oncology community
** Agreements include $200 mln in data licensing and model development fees to Tempus, co said
** The agreement with AstraZeneca expands on strategic partnership announced in 2021
** With move on the session, TEM shares up ~50% YTD. Stock hit intraday record high of $91.45 on Feb 14
** Tempus, backed by Japan's SoftBank 9984.T, went public last Jun in IPO priced at $37
** Of 12 analysts covering TEM, recommendation breakdown is 6 "strong buy" or "buy", rest "hold" and the median PT is $62, LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。